FAK-IN-22

FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC) . FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway[1].

Product Specifications

CAS Number

[2703920-02-7]

UNSPSC

12352211

Target

Akt; Apoptosis; Aurora Kinase; FAK; JAK; PI3K

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fak-in-22.html

Smiles

O=C(C1=CC=C(NC2=NC=C(C(F)(F)F)C(OC3=CC=CC4=C3C=CN4)=N2)C=C1)NC

Molecular Formula

C21H16F3N5O2

Molecular Weight

427.38

References & Citations

[1]Rong-Hong Zhang, et al. Discovery of a potent anticancer agent against pancreatic ductal adenocarcinoma targeting FAK with DFG-out state and JAK/Aurora kinases. Eur J Med Chem. 2025 Jan 15:282:117059.